Transition to ustekinumab in patients with moderate-to-severe psoriasis and inadequate response to methotrexate: A randomized clinical trial (TRANSIT)

British Journal of Dermatology

Volumn 170, Issue 2, 2014, Pages 425-434

  Paul, C ^a   Puig, L ^b   Kragballe, K ^c   Luger, T ^d   Lambert, J ^e   Chimenti, S ^f   Girolomoni, G ^g   Nicolas, J F ^h   Rizova, E ⁱ   Lavie, F ⁱ   Mistry, S ⁱ   Bergmans, P ^j   Barker, J ^k   Reich, K ^l,m  

^a SERVICE DE PNEUMOLOGIE   (France)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d UNIVERSITY OF MÜNSTER   (Germany)

^e GHENT UNIVERSITY   (Belgium)

^f TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^g UNIVERSITY OF VERONA   (Italy)

^h CENTRE HOSPITALIER LYON SUD   (France)

ⁱ Janssen Cilag 1 Rue Camille Desmoulins ^*  (United Kingdom)

^j Janssen Cilag BV Netherlands   (Netherlands)

^k KING'S COLLEGE LONDON   (United Kingdom)

^l DERMATOLOGIKUM HAMBURG   (Germany)

^m UNIVERSITY OF GÖTTINGEN   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODIES, MONOCLONAL, HUMANIZED; DERMATOLOGIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SUBSTITUTION; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; PSORIASIS; TREATMENT OUTCOME;

EID: 84894277192     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12646     Document Type: Article

References (27)

1. Pathirana D, Ormerod AD, Saiag P, et al,. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009; 23 (Suppl. 2): 1-70.
2. Leonardi CL, Kimball AB, Papp KA, et al,. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371: 1665-74.
3. Papp KA, Langley RG, Lebwohl M, et al,. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371: 1675-84.
4. Strober BE, Poulin Y, Kerdel FA, et al,. Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: efficacy and safety results from an open-label study. J Am Acad Dermatol 2011; 64: 671-81.
5. Krueger GG, Langley RG, Leonardi C, et al,. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007; 356: 580-92.
6. Reich K, Puig L, Paul C, et al,. One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in moderate-to-severe plaque psoriasis. Br J Dermatol 2014; 170: 435-444.
7. European Medicines Agency. Ustekinumab. Summary of Product Characteristics, updated September 2013. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000958/human-med-001065.jsp&mid=WC0b01ac058001d125&murl=menus/medicines/medicines.jsp (last accessed 13 November 2013).
8. Finlay AY, Khan GK,. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-16.
9. EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199-208.
10. Zigmond AS, Snaith RP,. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 1983; 67: 361-70.
11. Cardiff University. Dermatology Life Quality Index (DLQI). Frequently Asked Questions (FAQs), 2012. Available at: http://www.dermatology.org.uk/quality/dlqi/quality-dlqi-faqs.html (last accessed 13 November 2013).
12. EuroQol Group. Measuring self-reported population health: an international perspective based on EQ-5D, 2004. Available at: http://www.euroqol.org/fileadmin/user-upload/Documenten/PDF/Books/Measuring-Self-Reported-Population-Health-An-International-Perspective-based-on-EQ-5D.pdf (last accessed 13 November 2013).
13. Bjelland I, Dahl AA, Haug TT, et al,. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res 2002; 52: 69-77.
14. Opel D, Economidi A, Chan D, et al,. Two cases of hepatitis B in patients with moderate-to-severe psoriasis with ustekinumab. J Drugs Dermatol 2012; 11: 1498-501.
15. de Jong EM, Mørk NJ, Seijger MM, et al,. The combination of calcipotriol and methotrexate compared with methotrexate and vehicle in psoriasis: results of a multicentre placebo-controlled randomized trial. Br J Dermatol 2003; 148: 318-25.
16. Griffiths CE, Strober BE, van de Kerkhof P, et al,. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010; 362: 118-28.
17. European Medicines Agency. Methotrexate. Summary of Product Characteristics, updated July 2012. Available at: http://www.medicines.org.uk/emc/medicine/12034/SPC/ (last accessed 13 November 2013).
18. Berth-Jones J, Thompson J, Papp K,; Copenhagen Psoriasis Working Group. A study examining inter-rater and intrarater reliability of a novel instrument for assessment of psoriasis: the Copenhagen Psoriasis Severity Index. Br J Dermatol 2008; 159: 407-12.
19. Gourraud PA, Le Gall C, Puzenat E, et al,. Why statistics matter: limited inter-rater agreement prevents using the Psoriasis Area and Severity Index as a unique determinant of therapeutic decision in psoriasis. J Invest Dermatol 2012; 132: 2171-5.
20. McInnes IB, Kavanaugh A, Gottlieb AB, et al,. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 2013; 382: 780-9.
21. Reich K, Langley RG, Lebwohl M, et al,. Cardiovascular safety of ustekinumab in patients with moderate-to-severe psoriasis: results of integrated analyses of data from phase II and III clinical studies. Br J Dermatol 2011; 164: 862-72.
22. Heller MM, Wong JW, Nguyen TV, et al,. Quality-of-life instruments: evaluation of the impact of psoriasis on patients. Dermatol Clin 2012; 30: 281-91.
23. Mrowietz U, Kragballe K, Reich K, et al,. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 2011; 303: 1-10.
24. National Institute for Health and Care Excellence. Ustekinumab for the treatment of adults with moderate to severe psoriasis, August 2009. Available at: http://www.nice.org.uk/nicemedia/live/12038/45160/45160.pdf (last accessed 13 November 2013).
25. Khilji FA, Gonzalez M, Finlay AY,. Clinical meaning of change in Dermatology Life Quality Index scores. Br J Dermatol 2002; 147 (Suppl. 62): 50.
26. Hongbo Y, Thomas CL, Harrison MA, et al,. Translating the science of quality of life into practice: what do Dermatology Life Quality Index scores mean? J Invest Dermatol 2005; 125: 659-64.
27. Langley RG, Feldman SR, Han C, et al,. Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: results from a randomized, double-blind, placebo-controlled phase III trial. J Am Acad Dermatol 2010; 63: 457-65.